Prostate cancer :: a multidisciplinary approach to diagnosis and management /
"With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence...
Gespeichert in:
| Weitere Verfasser: | , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
DemosMedical,
[2015]
|
| Schriftenreihe: | Current multidisciplinary oncology.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | "With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description |
| Beschreibung: | 1 online resource (xxi, 412 pages) : illustrations (some color) |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781617051067 1617051063 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn898894164 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 141229t20152015nyua ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d YDXCP |d N$T |d E7B |d OCLCF |d EBLCP |d OCLCO |d MMU |d OCLCO |d OCLCQ |d OCLCO |d D6H |d LVT |d COCUF |d CNNOR |d MOR |d CCO |d PIFAG |d ZCU |d UAB |d AGLDB |d MERUC |d OCLCQ |d OCLCO |d OCLCA |d U3W |d OCLCA |d STF |d OCLCQ |d VTS |d ICG |d VT2 |d OCLCQ |d WYU |d G3B |d OCLCA |d TKN |d OCLCO |d DKC |d OCLCQ |d UKAHL |d OCLCQ |d OCLCA |d AJS |d OCLCO |d OCLCQ |d OCL |d OCLCO |d OCLCL |d UEJ |d OCLCO |d OCLCQ | ||
| 019 | |a 899158351 |a 1055395622 |a 1066511003 |a 1081230986 |a 1228551149 | ||
| 020 | |a 9781617051067 |q (electronic bk.) | ||
| 020 | |a 1617051063 |q (electronic bk.) | ||
| 020 | |z 9781936287598 |q (print) | ||
| 020 | |z 1936287595 |q (print) | ||
| 035 | |a (OCoLC)898894164 |z (OCoLC)899158351 |z (OCoLC)1055395622 |z (OCoLC)1066511003 |z (OCoLC)1081230986 |z (OCoLC)1228551149 | ||
| 050 | 4 | |a RC280.P7 | |
| 060 | 4 | |a WJ 762 | |
| 072 | 7 | |a HEA |x 039030 |2 bisacsh | |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 082 | 7 | |a 616.99/463 |2 23 | |
| 049 | |a MAIN | ||
| 130 | 0 | |a Prostate cancer (Dicker) | |
| 245 | 1 | 0 | |a Prostate cancer : |b a multidisciplinary approach to diagnosis and management / |c edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky. |
| 264 | 1 | |a New York : |b DemosMedical, |c [2015] | |
| 264 | 4 | |c ©2015 | |
| 300 | |a 1 online resource (xxi, 412 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Current multidisciplinary oncology series | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer. | |
| 520 | |a "With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description | ||
| 588 | 0 | |a Online resource; title from resource home page (ebrary, viewed November 2, 2015). | |
| 650 | 0 | |a Prostate |x Cancer |x Diagnosis. | |
| 650 | 0 | |a Prostate |x Cancer |x Treatment. | |
| 650 | 0 | |a Health care teams. |0 http://id.loc.gov/authorities/subjects/sh85059533 | |
| 650 | 0 | |a Prognosis. |0 http://id.loc.gov/authorities/subjects/sh85107299 | |
| 650 | 0 | |a Prostate-specific antigen. |0 http://id.loc.gov/authorities/subjects/sh2001002935 | |
| 650 | 1 | 2 | |a Prostatic Neoplasms |x diagnosis |
| 650 | 2 | 2 | |a Early Detection of Cancer |
| 650 | 2 | 2 | |a Patient Care Team |
| 650 | 2 | 2 | |a Prognosis |
| 650 | 2 | 2 | |a Prostate-Specific Antigen |
| 650 | 2 | 2 | |a Prostatic Neoplasms |x therapy |
| 650 | 6 | |a Prostate |x Cancer |x Traitement. | |
| 650 | 6 | |a Soins médicaux |x Travail en équipe. | |
| 650 | 6 | |a Pronostics (Pathologie) | |
| 650 | 6 | |a Antigène prostatique spécifique. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x Cancer. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a Prostate-specific antigen |2 fast | |
| 650 | 7 | |a Prognosis |2 fast | |
| 650 | 7 | |a Health care teams |2 fast | |
| 650 | 7 | |a Prostate |x Cancer |x Diagnosis |2 fast | |
| 650 | 7 | |a Prostate |x Cancer |x Treatment |2 fast | |
| 700 | 1 | |a Dicker, Adam P., |e editor. |1 https://id.oclc.org/worldcat/entity/E39PBJw8VkfpyRyxghK9wPTyh3 |0 http://id.loc.gov/authorities/names/nb2004312350 | |
| 700 | 1 | |a Kelly, Wm. Kevin |q (William Kevin), |e editor. |1 https://id.oclc.org/worldcat/entity/E39PCjtC4Q9wbQ4mHkwp3T7Vfq |0 http://id.loc.gov/authorities/names/n2009184487 | |
| 700 | 1 | |a Zaorsky, Nicholas G., |e editor, |e illustrator. |1 https://id.oclc.org/worldcat/entity/E39PCjDfqwGxhvwPJk9MWGcvwP |0 http://id.loc.gov/authorities/names/n2014187711 | |
| 700 | 1 | |a Trabulsi, Edouard J., |e editor. |1 https://id.oclc.org/worldcat/entity/E39PCjv6vXxytrhyv6mvbPgfG3 |0 http://id.loc.gov/authorities/names/n2014187713 | |
| 776 | 0 | 8 | |i Print version: |t Prostate cancer. |d New York : Demos, [2015] |z 9781936287598 |w (DLC) 2014033133 |w (OCoLC)888347032 |
| 830 | 0 | |a Current multidisciplinary oncology. |0 http://id.loc.gov/authorities/names/n2009183517 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=933020 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH35067689 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL1910141 | ||
| 938 | |a ebrary |b EBRY |n ebr11012595 | ||
| 938 | |a EBSCOhost |b EBSC |n 933020 | ||
| 938 | |a YBP Library Services |b YANK |n 12224201 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn898894164 |
|---|---|
| _version_ | 1816882298165919745 |
| adam_text | |
| any_adam_object | |
| author2 | Dicker, Adam P. Kelly, Wm. Kevin (William Kevin) Zaorsky, Nicholas G. Zaorsky, Nicholas G. Trabulsi, Edouard J. |
| author2_role | edt edt edt ill edt |
| author2_variant | a p d ap apd w k k wk wkk n g z ng ngz n g z ng ngz e j t ej ejt |
| author_GND | http://id.loc.gov/authorities/names/nb2004312350 http://id.loc.gov/authorities/names/n2009184487 http://id.loc.gov/authorities/names/n2014187711 http://id.loc.gov/authorities/names/n2014187713 |
| author_facet | Dicker, Adam P. Kelly, Wm. Kevin (William Kevin) Zaorsky, Nicholas G. Zaorsky, Nicholas G. Trabulsi, Edouard J. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC280 |
| callnumber-raw | RC280.P7 |
| callnumber-search | RC280.P7 |
| callnumber-sort | RC 3280 P7 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer. |
| ctrlnum | (OCoLC)898894164 |
| dewey-full | 616.99/463 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/463 |
| dewey-search | 616.99/463 |
| dewey-sort | 3616.99 3463 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>08497cam a2200829 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn898894164</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">141229t20152015nyua ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCF</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCO</subfield><subfield code="d">MMU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">D6H</subfield><subfield code="d">LVT</subfield><subfield code="d">COCUF</subfield><subfield code="d">CNNOR</subfield><subfield code="d">MOR</subfield><subfield code="d">CCO</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">UAB</subfield><subfield code="d">AGLDB</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCA</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">ICG</subfield><subfield code="d">VT2</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">G3B</subfield><subfield code="d">OCLCA</subfield><subfield code="d">TKN</subfield><subfield code="d">OCLCO</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">UEJ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">899158351</subfield><subfield code="a">1055395622</subfield><subfield code="a">1066511003</subfield><subfield code="a">1081230986</subfield><subfield code="a">1228551149</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781617051067</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1617051063</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781936287598</subfield><subfield code="q">(print)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1936287595</subfield><subfield code="q">(print)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)898894164</subfield><subfield code="z">(OCoLC)899158351</subfield><subfield code="z">(OCoLC)1055395622</subfield><subfield code="z">(OCoLC)1066511003</subfield><subfield code="z">(OCoLC)1081230986</subfield><subfield code="z">(OCoLC)1228551149</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.P7</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WJ 762</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039030</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">062000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99/463</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="130" ind1="0" ind2=" "><subfield code="a">Prostate cancer (Dicker)</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prostate cancer :</subfield><subfield code="b">a multidisciplinary approach to diagnosis and management /</subfield><subfield code="c">edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">DemosMedical,</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxi, 412 pages) :</subfield><subfield code="b">illustrations (some color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Current multidisciplinary oncology series</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from resource home page (ebrary, viewed November 2, 2015).</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Diagnosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Health care teams.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85059533</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prognosis.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85107299</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prostate-specific antigen.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2001002935</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Prostatic Neoplasms</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Early Detection of Cancer</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Patient Care Team</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Prognosis</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Prostate-Specific Antigen</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Prostatic Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Soins médicaux</subfield><subfield code="x">Travail en équipe.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pronostics (Pathologie)</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Antigène prostatique spécifique.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">Cancer.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Oncology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prognosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health care teams</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Diagnosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dicker, Adam P.,</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJw8VkfpyRyxghK9wPTyh3</subfield><subfield code="0">http://id.loc.gov/authorities/names/nb2004312350</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelly, Wm. Kevin</subfield><subfield code="q">(William Kevin),</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjtC4Q9wbQ4mHkwp3T7Vfq</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2009184487</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaorsky, Nicholas G.,</subfield><subfield code="e">editor,</subfield><subfield code="e">illustrator.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjDfqwGxhvwPJk9MWGcvwP</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014187711</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trabulsi, Edouard J.,</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjv6vXxytrhyv6mvbPgfG3</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014187713</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Prostate cancer.</subfield><subfield code="d">New York : Demos, [2015]</subfield><subfield code="z">9781936287598</subfield><subfield code="w">(DLC) 2014033133</subfield><subfield code="w">(OCoLC)888347032</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Current multidisciplinary oncology.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2009183517</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=933020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH35067689</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL1910141</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr11012595</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">933020</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12224201</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn898894164 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:26:23Z |
| institution | BVB |
| isbn | 9781617051067 1617051063 |
| language | English |
| oclc_num | 898894164 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xxi, 412 pages) : illustrations (some color) |
| psigel | ZDB-4-EBA |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | DemosMedical, |
| record_format | marc |
| series | Current multidisciplinary oncology. |
| series2 | Current multidisciplinary oncology series |
| spelling | Prostate cancer (Dicker) Prostate cancer : a multidisciplinary approach to diagnosis and management / edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky. New York : DemosMedical, [2015] ©2015 1 online resource (xxi, 412 pages) : illustrations (some color) text txt rdacontent computer c rdamedia online resource cr rdacarrier Current multidisciplinary oncology series Includes bibliographical references and index. Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer. "With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description Online resource; title from resource home page (ebrary, viewed November 2, 2015). Prostate Cancer Diagnosis. Prostate Cancer Treatment. Health care teams. http://id.loc.gov/authorities/subjects/sh85059533 Prognosis. http://id.loc.gov/authorities/subjects/sh85107299 Prostate-specific antigen. http://id.loc.gov/authorities/subjects/sh2001002935 Prostatic Neoplasms diagnosis Early Detection of Cancer Patient Care Team Prognosis Prostate-Specific Antigen Prostatic Neoplasms therapy Prostate Cancer Traitement. Soins médicaux Travail en équipe. Pronostics (Pathologie) Antigène prostatique spécifique. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Prostate-specific antigen fast Prognosis fast Health care teams fast Prostate Cancer Diagnosis fast Prostate Cancer Treatment fast Dicker, Adam P., editor. https://id.oclc.org/worldcat/entity/E39PBJw8VkfpyRyxghK9wPTyh3 http://id.loc.gov/authorities/names/nb2004312350 Kelly, Wm. Kevin (William Kevin), editor. https://id.oclc.org/worldcat/entity/E39PCjtC4Q9wbQ4mHkwp3T7Vfq http://id.loc.gov/authorities/names/n2009184487 Zaorsky, Nicholas G., editor, illustrator. https://id.oclc.org/worldcat/entity/E39PCjDfqwGxhvwPJk9MWGcvwP http://id.loc.gov/authorities/names/n2014187711 Trabulsi, Edouard J., editor. https://id.oclc.org/worldcat/entity/E39PCjv6vXxytrhyv6mvbPgfG3 http://id.loc.gov/authorities/names/n2014187713 Print version: Prostate cancer. New York : Demos, [2015] 9781936287598 (DLC) 2014033133 (OCoLC)888347032 Current multidisciplinary oncology. http://id.loc.gov/authorities/names/n2009183517 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=933020 Volltext |
| spellingShingle | Prostate cancer : a multidisciplinary approach to diagnosis and management / Current multidisciplinary oncology. Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer. Prostate Cancer Diagnosis. Prostate Cancer Treatment. Health care teams. http://id.loc.gov/authorities/subjects/sh85059533 Prognosis. http://id.loc.gov/authorities/subjects/sh85107299 Prostate-specific antigen. http://id.loc.gov/authorities/subjects/sh2001002935 Prostatic Neoplasms diagnosis Early Detection of Cancer Patient Care Team Prognosis Prostate-Specific Antigen Prostatic Neoplasms therapy Prostate Cancer Traitement. Soins médicaux Travail en équipe. Pronostics (Pathologie) Antigène prostatique spécifique. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Prostate-specific antigen fast Prognosis fast Health care teams fast Prostate Cancer Diagnosis fast Prostate Cancer Treatment fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85059533 http://id.loc.gov/authorities/subjects/sh85107299 http://id.loc.gov/authorities/subjects/sh2001002935 |
| title | Prostate cancer : a multidisciplinary approach to diagnosis and management / |
| title_alt | Prostate cancer (Dicker) |
| title_auth | Prostate cancer : a multidisciplinary approach to diagnosis and management / |
| title_exact_search | Prostate cancer : a multidisciplinary approach to diagnosis and management / |
| title_full | Prostate cancer : a multidisciplinary approach to diagnosis and management / edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky. |
| title_fullStr | Prostate cancer : a multidisciplinary approach to diagnosis and management / edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky. |
| title_full_unstemmed | Prostate cancer : a multidisciplinary approach to diagnosis and management / edited by Adam P. Dicker, William Kevin Kelly, Nicholas G. Zaorsky, Edouard J. Trabulsi ; illustrations by Nicholas G. Zaorsky. |
| title_short | Prostate cancer : |
| title_sort | prostate cancer a multidisciplinary approach to diagnosis and management |
| title_sub | a multidisciplinary approach to diagnosis and management / |
| topic | Prostate Cancer Diagnosis. Prostate Cancer Treatment. Health care teams. http://id.loc.gov/authorities/subjects/sh85059533 Prognosis. http://id.loc.gov/authorities/subjects/sh85107299 Prostate-specific antigen. http://id.loc.gov/authorities/subjects/sh2001002935 Prostatic Neoplasms diagnosis Early Detection of Cancer Patient Care Team Prognosis Prostate-Specific Antigen Prostatic Neoplasms therapy Prostate Cancer Traitement. Soins médicaux Travail en équipe. Pronostics (Pathologie) Antigène prostatique spécifique. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Prostate-specific antigen fast Prognosis fast Health care teams fast Prostate Cancer Diagnosis fast Prostate Cancer Treatment fast |
| topic_facet | Prostate Cancer Diagnosis. Prostate Cancer Treatment. Health care teams. Prognosis. Prostate-specific antigen. Prostatic Neoplasms diagnosis Early Detection of Cancer Patient Care Team Prognosis Prostate-Specific Antigen Prostatic Neoplasms therapy Prostate Cancer Traitement. Soins médicaux Travail en équipe. Pronostics (Pathologie) Antigène prostatique spécifique. HEALTH & FITNESS Diseases Cancer. MEDICAL Oncology. Prostate-specific antigen Health care teams Prostate Cancer Diagnosis Prostate Cancer Treatment |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=933020 |
| work_keys_str_mv | UT prostatecancerdicker AT dickeradamp prostatecanceramultidisciplinaryapproachtodiagnosisandmanagement AT kellywmkevin prostatecanceramultidisciplinaryapproachtodiagnosisandmanagement AT zaorskynicholasg prostatecanceramultidisciplinaryapproachtodiagnosisandmanagement AT trabulsiedouardj prostatecanceramultidisciplinaryapproachtodiagnosisandmanagement |